A Targeted and Responsive Nanoprodrug Delivery System for Synergistic Glioma Chemotherapy
Small · 2024-07 · 20 (30)
DOI: 10.1002/smll.202400630 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 03.03.2024. Verfasst von Weiling Zhuo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medic…. Hauptthemen laut MEDLINE: Glioma, Doxorubicin, Drug Delivery Systems, Prodrugs. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Sichuan Science and Technology Program, 1·3·5 Project for Disciplines of Excellence, West China Hospital, Sichuan University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Doxorubicin (DOX) is widely used as a chemotherapeutic agent for both hematologic and solid tumors and is a reasonable candidate for glioma treatment. However, its effectiveness is hindered by significant toxicity and drug resistance. Moreover, the presence of the blood–brain barrier (BBB) brings a crucial challenge to glioma therapy. In response, a GSH‐responsive and actively targeted nanoprodrug delivery system (cRGD/PSDOX‐Cur@NPs) are developed. In this system, a disulfide bond‐bridged DOX prodrug (PEG‐SS‐DOX) is designed to release specifically in the high glutathione (GSH) tumor environment, markedly reducing the cardiotoxicity associated with DOX. To further address DOX resistance, curcumin, serving as a P‐glycoprotein (P‐gp) inhibitor, effectively increased cellular DOX concentration. Consequently, cRGD/PSDOX‐Cur@NPs exhibited synergistic anti‐tumor effects in vitro. Furthermore, in vivo experiments validated the superior BBB penetration and brain‐targeting abilities of cRGD/PSDOX‐Cur@NPs, showcasing the remarkable potential for treating both subcutaneous and orthotopic gliomas. This research underscores that this nanoprodrug delivery system presents a novel approach to inhibiting glioma while addressing resistance and systemic toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for…
- Department of Laboratory Medicine, West China Second University Hospital, Sichuan University, Chengdu, 610041, China.
- Key Laboratory of Birth Defects and Related Diseases of Women and Children(Sichuan University), Ministry of Education, Chengdu, 610041, China.
- West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, 610041, China.
ORCID-Profile: Xiang Gao
Förderung
- National Natural Science Foundation of China
- Sichuan Science and Technology Program
- 1·3·5 Project for Disciplines of Excellence, West China Hospital, Sichuan University
Zitieren
APA
Zhuo, W., Wang, W., Zhou, W., Duan, Z., He, S., Zhang, X., Yi, L., Zhang, R., Guo, A., Gou, X., Chen, J., Huang, N., Sun, X., Qian, Z., Wang, X., & Gao, X. (2024). A Targeted and Responsive Nanoprodrug Delivery System for Synergistic Glioma Chemotherapy. Small, 20(30). https://doi.org/10.1002/smll.202400630
Vancouver
Zhuo W, Wang W, Zhou W, Duan Z, He S, Zhang X, et al. A Targeted and Responsive Nanoprodrug Delivery System for Synergistic Glioma Chemotherapy. Small. 2024;20(30). doi:10.1002/smll.202400630
BibTeX
@article{Zhuo2024,
author = {Zhuo, Weiling and Wang, Wanyu and Zhou, Wenjie and Duan, Zhongxin and He, Shi and Zhang, Xifeng and Yi, Linbin and Zhang, Rui and Guo, Anjie and Gou, Xinyu and Chen, Junli and Huang, Ning and Sun, Xiaodong and Qian, Zhiyong and Wang, Xiang and Gao, Xiang},
title = {A Targeted and Responsive Nanoprodrug Delivery System for Synergistic Glioma Chemotherapy},
journal = {Small},
year = {2024},
volume = {20},
number = {30},
doi = {10.1002/smll.202400630}
}
EUVIMED